The JPH2 Knockout A-549 Polyclonal Cells are derived from the A-549 human lung adenocarcinoma epithelial cell line through CRISPR/Cas9-mediated disruption of the junctophilin-2 (JPH2) gene. This polyclonal population comprises a heterogeneous mix of cells with diverse loss-of-function mutations at the JPH2 locus, minimizing clonal artifacts and enabling robust functional genomics studies, including pooled screens and signal transduction analyses.
A-549 cells originate from a 58-year-old Caucasian male with non-small cell lung cancer and exhibit adherent epithelial morphology. They serve as a widely used model for alveolar basal epithelial cells, retaining key malignant features such as deregulated proliferation, survival signaling, and partial differentiation. This background provides a clinically relevant context for exploring calcium signaling in lung adenocarcinoma, an emerging area in cancer biology.
Junctophilin-2 bridges the plasma membrane and endoplasmic/sarcoplasmic reticulum, forming junctional membrane complexes that orchestrate calcium microdomains. In excitable cells, JPH2 underpins excitation-contraction coupling; in non-muscle cells, it facilitates localized calcium signaling. Transcriptionally regulated by MEF2 and GATA4, and responsive to hypertrophic agonists such as endothelin-1 and angiotensin II, JPH2 interacts with caveolin-3, RyR2, IP3R, TRPC channels, and mitofusin-2. Downstream, it coordinates calcium-dependent activation of calmodulin, CaMKII, calcineurin, and NFATc3, modulating gene expression programs controlling cell growth, differentiation, and apoptosis.
In A-549 lung adenocarcinoma cells, JPH2 knockout disrupts junctional membrane architecture, dysregulating calcium homeostasis and impairing calcineurin-NFAT and CaMKII signaling. These pathways control proliferation, apoptosis, and epithelial-mesenchymal transition. As aberrant calcium handling contributes to cancer progression, metastasis, and drug resistance, this model enables dissection of JPH2-dependent calcium signaling in NSCLC, with polyclonal heterogeneity mirroring tumor complexity.
Typical applications include target validation, mechanistic pathway analysis, and functional genomics screens. Standard approaches encompass Western blotting for JPH2 and caveolin-3, RT-qPCR, immunofluorescence, and live-cell calcium imaging with Fluo-4 or Fura-2. Co-immunoprecipitation assays confirm JPH2?Ccaveolin-3 complex integrity, while phospho-specific analyses assess CaMKII and NFATc3 activation. Phenotypic assays??MTT/BrdU proliferation, wound-healing migration, and Annexin V/PI apoptosis??characterize calcium-dependent processes. For additional information or customization requests, please contact Ascent Research.
